Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Advances in diagnostics and targeted therapies have revolutionized oncology.
• Stratified medicine has emerged, linking targeted therapies to specific tumor molecular aberrations.
• Large-scale sequencing initiatives (e.g., Cancer Genome Atlas) highlight the importance of genome analysis in understanding cancer.

Purpose of the Study:

• To describe lessons learned from initial personalized cancer medicine (PCM) pilot initiatives.
• To explain how this knowledge is informing the design of novel clinical trials.
• To discuss the transformation of cancer care through molecular analysis and collaborative efforts.

Main Methods:

• Review of findings from early personalized cancer medicine pilot studies.
• Analysis of data from large-scale genomic projects and cancer mutation catalogs.
• Examination of collaborative efforts in cancer research and treatment.

Main Results:

• Pilot studies are transforming the analysis of tumor molecular aberrations.
• Clinical trial design and efficacy measurement are being redefined by PCM principles.
• Early initiatives provide valuable insights for future PCM research and application.

Conclusions:

• Personalized cancer medicine (PCM) is advancing through integrated genomic analysis and targeted therapies.
• Lessons from pilot studies are crucial for developing effective, personalized cancer treatment strategies.
• Collaborative research and data sharing are essential for the widespread adoption of PCM.